Price
$6.22
Decreased by -0.96%
Dollar volume (20D)
29.11 M
ADR%
8.03
Earnings report date
May 5, 2025
Shares float
73.67 M
Shares short
4.68 M [6.35%]
Shares outstanding
96.68 M
Market cap
607.16 M
Beta
0.91
Price/earnings
N/A
20D range
4.24 7.39
50D range
3.73 7.39
200D range
2.36 7.39

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough conditions targeting the central and peripheral nervous systems.

The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis.

It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations.

The company was incorporated in 2011 and is based in New Haven, Connecticut.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Mar 18, 25 -0.11
Decreased by -37.50%
-0.12
Increased by +6.06%
Nov 6, 24 -0.13
Decreased by -62.50%
-0.12
Decreased by -8.33%
Aug 8, 24 -0.12
Decreased by -71.43%
-0.11
Decreased by -9.09%
May 7, 24 -0.11
Decreased by -83.33%
-0.09
Decreased by -22.22%
Mar 20, 24 -0.08
Decreased by -33.33%
-0.09
Increased by +11.11%
Nov 9, 23 -0.08
Increased by +33.33%
-0.09
Increased by +11.11%
Aug 10, 23 -0.07
Increased by +50.00%
-0.08
Increased by +12.50%
May 11, 23 -0.06
Increased by +75.00%
-0.07
Increased by +14.29%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Dec 31, 24 0.00
Decreased by -100.00%
-11.41 M
Decreased by -45.95%
Decreased by N/A%
Decreased by N/A%
Sep 30, 24 0.00
Decreased by N/A%
-13.24 M
Decreased by -72.02%
Decreased by N/A%
Decreased by N/A%
Jun 30, 24 0.00
Decreased by N/A%
-12.35 M
Decreased by -72.88%
Decreased by N/A%
Decreased by N/A%
Mar 31, 24 0.00
Decreased by N/A%
-10.90 M
Decreased by -70.32%
Decreased by N/A%
Decreased by N/A%
Dec 31, 23 176.00 K
Increased by +N/A%
-7.82 M
Decreased by -42.10%
Decreased by -4.44 K%
Decreased by N/A%
Sep 30, 23 0.00
Decreased by N/A%
-7.70 M
Increased by +6.87%
Decreased by N/A%
Decreased by N/A%
Jun 30, 23 0.00
Decreased by N/A%
-7.14 M
Increased by +11.26%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 0.00
Decreased by N/A%
-6.40 M
Increased by +12.66%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY